Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M LoRusso

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Neuro-Oncology|January 1, 1988
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literatureP M LoRusso, E Tapazoglou, R J Zarbo, et al.
American Journal of Clinical Oncology|August 1, 1995
Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancerP M LoRusso, P L Lomen, B G Redman, et al.
Cancer|February 15, 1996
Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood as a marker of breast cancerZ Djuric, L K Heilbrun, M S Simon, et al.
Cancer Research|September 15, 1990
Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systemsP M LoRusso, S L Aukerman, L Polin, et al.
Journal of the National Cancer Institute|February 16, 1994
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrowR E Parchment, D A Volpe, P M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathwaysZ Ding, R E Parchment, P M LoRusso, et al.
Investigational New Drugs|January 1, 1996
Preclinical antitumor activity of CI-994P M LoRusso, L Demchik, B Foster, et al.
Investigational New Drugs|July 30, 1999
Preclinical antitumor activity of XK469 (NSC 656889)P M LoRusso, R Parchment, L Demchik, et al.
Investigational New Drugs|April 9, 2001
Chronic oral administration of CI-994: a phase 1 studyS Prakash, B J Foster, M Meyer, et al.
British Journal of Cancer|May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)G K Schwartz, P M LoRusso, M A Dickson, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Neuro-Oncology|January 1, 1988
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literatureP M LoRusso, E Tapazoglou, R J Zarbo, et al.
American Journal of Clinical Oncology|August 1, 1995
Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancerP M LoRusso, P L Lomen, B G Redman, et al.
Cancer|February 15, 1996
Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood as a marker of breast cancerZ Djuric, L K Heilbrun, M S Simon, et al.
Cancer Research|September 15, 1990
Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systemsP M LoRusso, S L Aukerman, L Polin, et al.
Journal of the National Cancer Institute|February 16, 1994
In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrowR E Parchment, D A Volpe, P M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathwaysZ Ding, R E Parchment, P M LoRusso, et al.
Investigational New Drugs|January 1, 1996
Preclinical antitumor activity of CI-994P M LoRusso, L Demchik, B Foster, et al.
Investigational New Drugs|July 30, 1999
Preclinical antitumor activity of XK469 (NSC 656889)P M LoRusso, R Parchment, L Demchik, et al.
Investigational New Drugs|April 9, 2001
Chronic oral administration of CI-994: a phase 1 studyS Prakash, B J Foster, M Meyer, et al.
British Journal of Cancer|May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)G K Schwartz, P M LoRusso, M A Dickson, et al.
Pageof 3